Eli Lilly has agreed to buy biopharmaceutical company Morphic Holding for $3.2 billion in a deal that bolsters the drugmaker’s immunology pipeline.
Related Posts
Energy & Utilities Roundup: Market Talk
TotalEnergies, Enbridge and more in the latest Market Talks covering Energy and Utilities.
Microsoft Shares Slip as Outlook Sparks Concern About AI and Cloud Revenue
Company’s projection points to less growth than analysts had anticipated
Turo, the Car-Share App Used in Two Attacks, Is No Stranger to Safety Concerns
After rented vehicles rammed into a crowd in New Orleans and exploded in Las Vegas, some users say a reckoning of the firm’s practices is […]